CORD-19:35349bb1fc9290338907b7d7f104c9db3951163b / 0-220 JSONTXT

{"project":"CORD-PICO","denotations":[{"id":"p1_all0","span":{"begin":34,"end":81},"obj":"Intervention"},{"id":"p2_i0","span":{"begin":34,"end":66},"obj":"Pharmacological"},{"id":"p2_i1","span":{"begin":74,"end":81},"obj":"Control"}],"text":"ABSTRACTS C01 Pharmacodynamics of Entresto® (Sacubitril/Valsartan) Versus Placebo in Dogs with Preclinical Myxomatous Mitral Valve Disease C02 Trimethylamine-N-Oxide and its Precursors in Dogs with Degenerative Mitral Va"}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1","span":{"begin":118,"end":130},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002135"}],"text":"ABSTRACTS C01 Pharmacodynamics of Entresto® (Sacubitril/Valsartan) Versus Placebo in Dogs with Preclinical Myxomatous Mitral Valve Disease C02 Trimethylamine-N-Oxide and its Precursors in Dogs with Degenerative Mitral Va"}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1","span":{"begin":118,"end":138},"obj":"Disease"},{"id":"T20315","span":{"begin":118,"end":138},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A14104","pred":"mondo_id","subj":"T20315","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"}],"text":"ABSTRACTS C01 Pharmacodynamics of Entresto® (Sacubitril/Valsartan) Versus Placebo in Dogs with Preclinical Myxomatous Mitral Valve Disease C02 Trimethylamine-N-Oxide and its Precursors in Dogs with Degenerative Mitral Va"}